13 January 2011 -- Circadian Technologies (ASX.CIR) is very pleased to announce today that its subsidiary company
Vegenics Pty Limited, has been granted an exclusive, global licence by Chugai Pharmaceutical Co,
Ltd. granting access to Chugai IP relating to VEGF-D.
Circadian and Chugai both hold extensive VEGF-D IP portfolios which have overlapped throughout
This licence enables Circadian to enhance its intellectual property portfolio and secure its position as
the dominant player in respect of VEGF-D worldwide.
Importantly, the agreement allows Circadian to sub-licence the IP which will enable us to expand our
work in utilising our VEGF-D intellectual property estate through selective partnerships.
Circadian will pay an upfront licence fee to Chugai, and milestone payments and royalties on certain
VEGF-D related products.
Mr Robert Klupacs, CEO of Circadian said: “It is a great honour for us that such a well regarded
company as Chugai - a major player in Japan and part of the Roche group - has the confidence in our
product development and commercialisation skills to grant us a licence to their intellectual property.
VEGF-D is a major novel target for cancer and other diseases, including respiratory diseases, and as
such is an important asset for Circadian. In addition to further underpinning our own VEGF-D
related drug development programs, this agreement enhances our ability to use VEGF-D to develop
new diagnostics and treatments and to potentially generate further early revenues for Circadian.”
Managing Director - Circadian
Tel: +61 (0) 3 9826 0399
Media Enquiries – Australia:
Tel: +61 (0) 3 9866 4722
Media Enquiries –
The Trout Group LLC
251 Post Street, Suite 412
San Francisco, CA 94108
Tel +1 215 740 8468
About Circadian Technologies Limited
Circadian (ASX:CIR) is a biologics drug developer focusing on cancer therapies. It controls
exclusive worldwide rights to a significant intellectual property portfolio around Vascular
Endothelial Growth Factor (VEGF) C and D. The applications for the VEGF technology, which
functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian’s
internal product development programs are focussed on novel anti-cancer therapeutics for large
unmet needs. Circadian has also licensed rights to some parts of its intellectual property portfolio for
the development of other products to ImClone Systems (a wholly owned subsidiary of Eli Lilly &
Company - NYSE: LLY). ImClone Systems is currently developing an antibody-based drug
targeting VEGFR-3 for the treatment of solid tumours.
Chugai is the number 1 biopharmaceutical company in Japan. And is part of the Roche Group of
companies being 52% owned by Hoffman La-Roche. Its 2009 revenues were approximately
$US4.6B and it employs over 6400 people worldwide. Chugai markets and develops new innovative
products in oncology, bone and joint disease, renal disease, Transplantation,immunology and
infectious disease. It recently launched Avastin into the Japanese market.
About Circadian’s pipeline of treatments for cancer
The clinical and outstanding commercial success of Avastin, an antibody that blocks the activity of
VEGF-A, clinically validated anti-angiogenic drugs as an effective means of inhibiting solid tumour
growth. By blocking the interaction of VEGF-A with its receptors, primarily VEGFR-2, the multi-
billion dollar cancer therapeutic slows tumour growth by inhibiting blood vessel recruitment into the
tumour, effectively starving tumours of essential nutrients and oxygen required for growth. Avastin,
which is sold by Genentech, now part of Roche, had U.S. sales in 2009 of US$5.7 billion and
worldwide sales in excess of US$8.6 billion. Avastin is approved by the US FDA in the following
indications: metastatic colorectal cancer, non-squamous-cell lung cancer, metastatic breast cancer,
glioblastoma, metastatic renal cell carcinoma.
The VEGF-C inhibitor, VGX-100, a key therapeutic in Circadian’s portfolio, block this alternative
stimulator for VEGFR-2. As such, it has the potential to block blood vessel growth in tumours
resistant to anti-VEGF-A therapy and, when used in combination with drugs like Avastin, may
completely shut down angiogenesis (the growth of blood vessels) mediated by VEGFR-2, resulting
in greater clinical efficacy.
VEGF-C along with the molecule VEGF-D. are also the only known proteins to bind and activate
VEGFR-3 which drives lymphatic vessel and tumour-associated blood vessel growth. Inhibitors of
VEGF-C thus have therapeutic potential to inhibit not only primary tumour growth through their
anti-angiogenic activities, but to also inhibit tumour spread or metastasis via the lymphatic vessels - a
mechanism of tumour dissemination that is often the deadliest aspect of many tumour types and a
mechanism that is not effectively blocked by
anti-VEGF-A or anti-VEGFR-2 therapeutics.
Inherent risks of Investment in Biotechnology Companies
There are a number of inherent risks associated with the development of pharmaceutical products to
a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a
drug prior to commercialisation and a significant proportion of drugs fail one or both of these
criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent
applications and issued patents will offer adequate protection to enable product development, the
obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid
advancements in technology. Companies such as Circadian are dependent on the success of their
research and development projects and on the ability to attract funding to support these activities.
Investment in research and development projects cannot be assessed on the same fundamentals as
trading and manufacturing enterprises. Thus investment in companies specialising in drug
development must be regarded as highly speculative. Circadian strongly recommends that
professional investment advice be sought prior to such investments.
Certain statements in this ASX announcement may contain forward-looking statements regarding
Company business and the therapeutic and commercial potential of its technologies and products in
development. Any statement describing Company goals, expectations, intentions or beliefs is a
forward-looking statement and should be considered an at-risk statement. Such statements are
subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the
process of developing technology and in the process of discovering, developing and commercialising
drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavor
of building a business around such products and services. Circadian undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new information, future
events, or otherwise. Actual results could differ materially from those discussed in this ASX